- Market Capitalization, $K 839,980
- Shares Outstanding, K 88,326
- Annual Sales, $ 23,960 K
- Annual Income, $ -36,250 K
- 60-Month Beta 2.65
- Price/Sales 23.36
- Price/Cash Flow N/A
- Price/Book 15.23
|Period||Period Low||Period High||Performance|
| || |
+1.17 (+14.03%)since 03/16/21
| || |
+2.63 (+38.23%)since 01/15/21
| || |
+7.35 (+340.28%)since 04/16/20
XOMA Corporation (Nasdaq: XOMA) today announced its portfolio of potential future milestone and royalty assets has increased with the addition of three Affimed N.V. (Nasdaq: AFMD) innate cell engager (ICE)...
NEW YORK, NY / ACCESSWIRE / April 15, 2021 / Affimed NV (NASDAQ:AFMD) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on April 15, 2021 at 8:30 AM Eastern...
Companies in the news are: AFMD, FUBO, GENE, CELC
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AFMD, GOVX, TXMD, FBIO, and FUBO.
Affimed (AFMD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AFMD, KURA, MTNB, UEC, and SENS.
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 33.33% and 94.55%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
HEIDELBERG, Germany (AP) _ Affimed N.V. (AFMD) on Tuesday reported a loss of $7 million in its third quarter.
-- Pre-clinical data substantiates synergy between Affimed's ICE molecules and both NKMax America's autologous and cryopreserved allogeneic NK cell therapy products
Affimed N.V. (AFMD) delivered earnings and revenue surprises of -50.00% and -52.45%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
|Bioshares Biotech Clinical Trial|
|Ai Powered International Equity ETF|
|Alps Medical Breakthroughs ETF|
|Micro-Cap Ishares ETF|
|Defiance Nasdaq Junior Biotechnology ETF|